Jumex

Selegiline Hydrochloride, the active ingredient in Jumex, is a monoamine oxidase B (MAO‑B) inhibitor presented as a tablet for oral use. It is employed as an adjunct therapy in Parkinson’s disease to enhance motor function in adult patients, and is also used off‑label for depressive disorders.

GNH USA supplies Jumex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch. Customers benefit from reliable logistics and responsive technical support.

Selegiline Hydrochloride acts on the monoamine oxidase B pathway, providing therapeutic benefit in specific neurological and psychiatric conditions, primarily by enhancing dopaminergic activity and modulating neurotransmitter balance. - Parkinson's disease (adjunct therapy): improves motor symptoms and reduces “off” periods when combined with levodopa. - Major depressive disorder (off‑label): may augment antidepressant response in patients with treatment‑resistant depression. - Early‑stage Parkinson's disease: may delay the need for levodopa initiation by preserving dopaminergic neurons.

Selegiline Hydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild stomach upset that may resolve with food. - Headache: transient pain often relieved by analgesics. - Dizziness or light‑headedness: sensation of imbalance, especially when standing quickly.

Serious or Rare Side Effects: - Hypertensive crisis with tyramine‑rich foods: sudden high blood pressure that can be life‑threatening. - Serotonin syndrome when combined with serotonergic drugs: agitation, fever, rapid heart rate, and muscle rigidity. - Severe liver injury or hepatitis: jaundice, elevated liver enzymes, and possible hepatic failure.

When prescribing Selegiline Hydrochloride, clinicians should observe several precautionary measures to minimize risks. - Monitor blood pressure: check for orthostatic changes and hypertensive episodes. - Avoid tyramine‑rich foods: restrict aged cheeses, cured meats, and fermented products. - Review concomitant serotonergic medications: assess risk of serotonin syndrome. - Assess liver function: perform baseline and periodic liver enzyme tests. - Use caution in patients with cardiovascular disease: evaluate cardiac status before initiation. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Selegiline Hydrochloride has notable drug interactions that require careful management.

Major Interactions (Avoid): - Tyramine‑containing foods and beverages: can precipitate hypertensive crisis. - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): increase risk of serotonin syndrome. - Meperidine and other opioid analgesics: may cause severe hypertension or serotonin toxicity. - Linezolid and other MAO‑inhibiting antibiotics: potentiate MAO inhibition leading to dangerous reactions. - Decongestants containing pseudoephedrine: can elevate blood pressure excessively.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may enhance hypotensive effects, requiring dose adjustment. - Anticholinergic drugs: can worsen dry mouth and cognitive effects. - Other MAO inhibitors: combined effect may lead to excessive MAO blockade. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of bleeding. - Central nervous system depressants: may augment sedation.